

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 March 2008 (20.03.2008)

PCT

(10) International Publication Number
WO 2008/032238 A2

(51) International Patent Classification: **Not classified**

(21) International Application Number:
PCT/IB2007/053553

(22) International Filing Date:
4 September 2007 (04.09.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
06120569.6 13 September 2006 (13.09.2006) EP

(71) Applicant (for all designated States except US): **KONINKLIJKE PHILIPS ELECTRONICS N. V.** [NL/NL];
Groenewoudseweg 1, NL-5621 BA Eindhoven (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KRIJNSEN, Hendrika, C.** [NL/NL]; c/o High Tech Campus 44, NL-5656 AE Eindhoven (NL). **IORDANOV, Ventseslav, P.** [BG/NL]; c/o High Tech Campus 44, NL-5656 AE Eindhoven (NL). **LANGEREIS, Geert** [NL/NL]; c/o High Tech Campus 44, NL-5656 AE Eindhoven (NL). **VAN BRUGGEN, Michel, P., B.** [NL/NL]; c/o High Tech

Campus 44, NL-5656 AE Eindhoven (NL). **ACKERMANS, Paul, A., J.** [NL/NL]; c/o High Tech Campus 44, NL-5656 AE Eindhoven (NL).


(74) Agent: **SCHOUTEN, Marcus M.**; High Tech Campus 44, NL-5656 AE Eindhoven, (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: DEVICE FOR AUTOMATIC ADJUSTMENT OF THE DOSE OF MELATONIN AND/OR DELIVERY OF MELATONIN



(57) Abstract: The invention relates to a device for melatonin treatment involving an adapting means which adapts the daily dose upon measurement of a body parameter of the patient or the user of the device.

WO 2008/032238 A2



Published:

- *without international search report and to be republished
upon receipt of that report*

DEVICE FOR AUTOMATIC ADJUSTMENT OF THE DOSE OF MELATONIN
AND/OR DELIVERY OF MELATONIN

5

This invention is in the field of devices for automatic adjustment of the dose of melatonin and/or delivery of melatonin

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesized and secreted by the pineal gland. The exact function of the hormone in adult human
10 beings has not been determined. In healthy young adults, melatonin is secreted as a broad pulse during nighttime sleep in the total amount of approximately 25 - 30 µg per night, producing peak plasma concentrations of approximately 70 pg/ml, occurring at approximately 02:00 am. Melatonin is secreted into the blood stream and possibly also into cerebrospinal fluid (CSF) simultaneously. The terminal plasma
15 elimination half-life is approximately 45 minutes; volume of distribution is approximately 40 liters; and the metabolic clearance of melatonin is approximately 1 liter per minute

The relationship of the melatonin cycle to the activity/rest (sleep) cycle is not clear, but it is believed that melatonin organizes at least partially the
20 normal sleep pattern.

Melatonin has been given to human beings to treat the phenomenon of "jet lag" following airplane trips associated with a change in time zones (Arendt
25 et al. (1987) *Ergonomics* 30:1379-1393); U.S. Pat. Nos. 4,600,723 and 4,665,086). It has been given to patients with Parkinson disease (Anton-Tay et al. (1971) *Life Sciences* 10:841-850), epilepsy (Anton-Tay et al., *ibid.*), or seasonal affective disorders (Wirz-Justice et al. (1990) *J. Psychiat. Res.* 24(2) :129-137). It has been tried as a sleep-wake organizer in desynchronized blind persons (Arendt et al.
30 (1988) *Lancet* pp 772-773; Folkard et al. (1990) *Neuroscience Lett.* 113:193-198; Sack et al., (1987) in, "Temporal Disorder in Human Oscillatory Systems", Eds. L. Rensing et al., Springer- Verlag, Heidelberg, pp 219-224; Sack and Lewy (1988)

- 2 -

Am. Psychiatric Assoc. 141 Ann. Meeting, Montreal, Quebec). Improved timing of sleep cycles resulted. Oral melatonin has been given to insomniacs (Waldhouser et al. (1990) *Psychopharmacology* 100:222-226; Arendt et al. (1991) *Lancet* 337:1121-1124). Melatonin reduced the time awake before sleep onset and

5 diminished sleep latency and number of awakenings. Overall sleep efficiency was increased, and mood, drive, alertness, and reaction time were improved the next day. Most of the published studies are consistent with the assumption that melatonin has mild sedative and hypnotic properties and may be a natural, sleep-inducing and sleep-organizing signal in humans. In addition, melatonin has been reported to lower

10 intraocular pressure in glaucoma, to inhibit breast cancer (U.S. Pat. No. 4,855,305; Barch et al. (1991) *Cancer* 67:1681-1684), to be useful in the treatment of premenstrual depression (U.S. Pat. No. 4,945, 103; Parry et al. (1990) *Arch. Gen. Psychiatry* 47:1139-1146; Yen et al. (1990) *Arch. Gen. Psych.* 47:1139-1146), for affecting contraception in humans (PCT Appln. WO 90/14084), and to prevent

15 sudden infant death syndrome (Wurtman et al. (1990) *Forensic Science Internatl.* 45:171-180).

However, especially since melatonin is also an endogenous compound, it has been found that the optimal dosage is often difficult and the effect of under and/or overdosage often occurs. This is at least in part due to the circadian

20 rhythms that trigger the anabolism and catabolism of melatonin in the human body.

It is therefore an object of the present invention to provide a device for automatic adjustment of the dose of melatonin and/or delivery of melatonin

25 which is for most applications capable to respond to the changes, especially changes in biological functions over time.

This object is solved by a device according to claim 1 of the present invention. Accordingly, a device for automatic adjustment of the dose of melatonin and/or delivery of melatonin is provided, comprising

- 3 -

- a) a measuring means, which measures at least one body parameter of a patient for at least ≥ 1 measuring cycle;
- b) an adapting means, which adapts and/or changes the dose of melatonin according to the measuring data of the measuring means;
- 5 c) a delivery device for delivering melatonin to a person to be treated and/or a user of the device.

The term “adapting and /or changing” especially means and/or includes that the dose of melatonin is adapted and/or changed in order to reach a desired sleep pattern and/or interval.

10 By doing so, at least one of the following advantages is achieved for most of the applications within the present invention:

- For a wide range of applications within the present invention, no initial longer term measurements are needed that have to be analysed before the therapy can start. This allows for a wide range of applications within the present invention to speed-up the therapy process providing an earlier start;
- 15 - For a wide range of applications within the present invention, less side effects can be noticed;
- For a wide range of applications within the present invention the therapeutic dose may be increased to increase treatment efficacy;
- 20 - For a wide range of applications within the present invention, the drug amount is automatically adjusted upon the patient’s endogenous hormone production;
- For a wide range of applications within the present invention, the drug amount gradually converges to the desired outcome (i.e. sleep interval).
- 25

According to a preferred embodiment of the present invention, the at least one body parameter includes body temperature, core body temperature, skin surface temperature, activity, melatonin level, cortisol level, heart rate, breathing frequency.

30 According to a preferred embodiment of the present invention, the adapting means adapts and/or changes the dose of melatonin in order to reach a

- 4 -

selected day/night activity ratio. In most cases this ratio has shown to be approximately 100:5 to 100:20 for a wide range of applications within the present invention.

According to a preferred embodiment of the present invention, the device comprises further a normalizing means to generate at least one normalized curve out of the data measured by the measuring means.

The term “normalized curve” means and/or includes especially that from the data derived from the measuring cycles, the normalizing curve is calculated by the equation:

$$Z = (X - \text{mean}(X)) / \text{standard deviation} * 100\%$$

with X (also written as X_t) being the body parameter and $\text{mean}(X)$ being the mathematical mean of X_t over a defined period. It should be noticed that usually X may have both positive and negative values.

However, in case the first body parameter includes activity, for a wide range of applications within the present invention the normalizing curve is calculated as follows:

Taking the average diurnal activity, taking the actual average (e.g. measured in an interval of 10 to 30 minutes) activity and dividing the actual average activity by the average diurnal activity.

According to a preferred embodiment of the present invention, the daily dose and/or dose for a certain time period of melatonin is set as to be

$$\text{previous dose} + \Delta \text{melatonin } [\Delta m],$$

with the previous dose being the daily dose of the previous day or time period, whereby Δm is changed and/or set each time period, at least every 14 days, preferably at least every week, but most preferably daily (or for the next time period) according to the data of the measuring means.

It should be noted that the term “changed and/or set according to” does not mean that Δm is changed on the basis of the measuring means alone;

- 5 -

however, according to the preferred embodiment, the data of the measuring means are taken into account when changing and/or setting Δm .

According to a preferred embodiment of the present invention, Δm is $\leq 50 \mu\text{g/day}$, preferably $\leq 40 \mu\text{g/day}$. This has been shown to be best suitable for a wide range of applications within the invention.

According to a preferred embodiment of the present invention, $|\Delta m|$ is $\geq 0\%$ and $\leq 80\%$ of the maximum dose change Δm_{max} . By doing so, it has been shown for a wide range of applications within the present invention that “overdosing” due a too high Δm can be avoided.

According to a preferred embodiment of the present invention, Δm is set as

$$\Delta m \geq [\Delta m_{\text{max}} * (\text{ratio} - a)/(1-a)] * 0.8 \text{ and } \leq [\Delta m_{\text{max, melatonin}} * (\text{ratio} - a)/(1-a)] * 1.2$$

with Δm_{max} being the maximum dosage change of melatonin (preferably $\leq 50 \mu\text{g/day}$ more preferred $\leq 40 \mu\text{g/day}$), ratio being the actual ratio between nocturnal and diurnal activity and a being the desired ratio between nocturnal and diurnal activity (≤ 0.25 , corresponding with a day/night activity of 100:25, but preferably ≤ 0.10).

According to another embodiment of the present invention, the amount of melatonin delivered is decreased when the ratio and a have differed ≤ 0.1 (i.e. that $|\text{ratio} - a|$ is ≤ 0.1), preferably ≤ 0.05 for at least one measurement cycle, preferably for at least 5 measurement cycles. By doing so, it is possible for a wide range of applications within the present invention to smoothen the adjustment to the preselected ratio and limit melatonin delivery when the endogenous production takes over such as in the treatment of the delayed sleep phase syndrome.

According to a preferred embodiment of the present invention, the decrease in daily melatonin is $\leq 20\%$ per day and $\geq 5\%$ per day of the dosage of the previous day until m (melatonin dosage) is $\leq 2.5 \mu\text{g/day}$, preferably $\leq 1.0 \mu\text{g/day}$. This range has been shown within a wide range of applications of the present

- 6 -

invention to be most effective while lessening the probability of relapses.

According to a further embodiment of the present invention, while gradually decreasing the daily melatonin dosage, the measuring means is still used and the adapting means becomes active again once the $\left| \text{ratio} - a \right|$ is no longer $\leq$
5 0.1.

According to a preferred embodiment of the present invention, when the melatonin dosage drops below 2.5 μg /day, preferably below 1.0 μg /day, the dosage is set to zero.

According to an embodiment of the present invention, the device
10 furthermore comprises a storing means for storing data on the daily melatonin dose, profile and/or activity. This has shown to be advantageous for a wide range of applications within the present invention. According to an embodiment of the present invention, the data stored can be read by the user only, according to a further embodiment of the present invention, the data stored can be read by the user
15 and / or other persons e.g., a physician.

According to an embodiment of the present invention, the stored data can be used to stop the delivery of melatonin when the dosing amount has exceeded a certain preset threshold and/or the effectiveness of the melatonin treatment is below a certain other threshold.

20 According to an embodiment of the present invention, the stored data can be used to provide information that the delivery of melatonin has stopped after the device slowly decreased the daily amount of melatonin delivery.

According to a preferred embodiment of the present invention, the delivery of melatonin occurs along a drug delivery profile. By doing so it has been
25 shown for a wide range of applications within the present invention that problems and/or inefficacies due to catabolic mechanisms of melatonin in the human body can be avoided or at least be reduced.

According to a preferred embodiment of the present invention, the drug delivery profile includes an increasing delivery phase whereby the amount of
30 delivered melatonin increases with $\geq 1\%$ and $\leq 12\%$ per hr, preferably 5% and $\leq 10\%$ per hr of the total daily melatonin dosage.

- 7 -

According to a preferred embodiment of the present invention, the drug delivery profile includes that the maximum delivery of melatonin in 1 hr is ≥ 10 % and ≤ 30 % of the total daily melatonin dosage. According to a preferred embodiment of the present invention, the drug delivery profile includes a decreasing
5 delivery phase whereby the amount of delivered melatonin decreases with ≥ 1 % and ≤ 12 % per hr, preferably 5 % and ≤ 10 % per hr of the total daily melatonin dosage.

According to a preferred embodiment of the present invention, the adapting means is able to take into account information supplied by the person to be treated and/or a user of the device. Such information may include – but not be
10 limited to – the judgement of the user of its own sleep pattern, a desired sleep interval and/or information of a physician concerning the status of the person to be treated.

According to a preferred embodiment of the present invention, the device comprises an input means for inputting the data from the person to be treated
15 and/or a user of the device. These input means may include – but not be limited to – buttons or keys, interfaces for communication with e.g. computers in hospitals or doctor's surgery and/or means for wireless communication.

According to a preferred embodiment of the present invention, the delivery device comprises a patch or has a patch-like build-up. This has proved to
20 be beneficial for a wide range of applications especially for users and/or patients who suffer from DSPS or other syndromes, which are more of a temporary nature.

According to a different preferred embodiment of the present invention, the delivery device comprises an implant or has an implant-like build-up. This has proved to be beneficial for a wide range of applications especially for users
25 and/or patients who suffer from chronic sleep disturbances, e.g. in connection with Alzheimer.

The present invention furthermore relates to a method for the controlled release of drugs, comprising the steps of

- a) measuring at least one body parameter of the patient for at least ≥ 1
30 measuring cycle;
- b) adapting and/or changing the dose of melatonin on account of the

- 8 -

measured data of the measuring means;

- c) delivering melatonin to a person to be treated and/or a user of the device.

A device and /or a method according to the present invention may be of use in a wide variety of systems and/or applications, amongst them one or more of the following:

- medical devices for the automatic adjustment of and/or delivery of melatonin;
- Jet-lag treatment devices.

The aforementioned components, as well as the claimed components and the components to be used in accordance with the invention in the described embodiments, are not subject to any special exceptions with respect to their size, shape, material selection and technical concept such that the selection criteria known in the pertinent field can be applied without limitations.

15

BRIEF DESCRIPTION OF THE DRAWINGS

Additional details, features, characteristics and advantages of the object of the invention are disclosed in the dependent claims, the figures and the following description of the respective figures, tables and examples, which -- in an exemplary fashion -- show one example of a melatonin treatment (i.e. dosage change) according to the invention.

20

25

30

Fig. 1 shows four diagrams of activity against time of activity during the day prior to melatonin treatment, on day 1 and 2 of melatonin treatment and a desired idealized activity curve ("day x");

Fig. 2 shows three diagrams of activity against time of activity during the day prior to melatonin treatment (same as in Fig. 3), on day 3 of melatonin treatment and a desired idealized activity curve ("day x", same as in Fig. 1);

Fig. 3 shows three diagrams of delivery of melatonin against clock

time showing the three drug delivery profiles of the melatonin treatment of day 1 to 3;

Fig. 4 shows a schematic partial cut-out side view of a delivery device according to a first embodiment of the present invention implemented in a watch;

Fig. 5 shows a top view of the device of Fig. 4 approximately along line II-II in Fig. 4;

Fig. 6 shows a flow chart of an implementation of a method according to a first embodiment of the present invention.

10

Fig. 1 shows four diagrams of activity against time of activity during the day prior to melatonin treatment, on day 1 and 2 of melatonin treatment and a desired idealized activity curve ("day x"), whereby the daily dose of melatonin was changed according to one embodiment of the present invention. It should be noted that the datapoints in Figs. 1 and 2 have been averaged per hour (so that one datapoint is given for every hour).

The desired period of sleep was set from 23:00 to 7:00, however, prior to treatment the activity curve was clearly shifted with activity until about 3:00 and rising at about 11:00 (This data was used from a person suffering from delayed sleep phase syndrom (DSPS)).

20

Fig. 2 additionally shows the activity curve of day 3. It can clearly be seen that the desired idealized curve ("day x") is approximated very well already on the third day of treatment.

The data of Fig. 1 and 2 is given in the table I hereafter

25

Table I: Normalized average hourly activity

Clock time	prior to treatment	Day 1	Day 2	Day 3	"Day X"
18:00	106	90	93	74	78
19:00	88	101	100	96	95
20:00	103	75	74	107	105

- 10 -

21:00	78	97	95	108	104
22:00	93	110	108	106	103
23:00	113	104	107	12	7
00:00	102	105	108	5	5
01:00	106	96	6	4	4
02:00	99	5	5	5	5
03:00	5	5	4	6	5
04:00	4	4	5	5	5
05:00	5	6	6	4	4
06:00	6	5	5	5	6
07:00	5	4	4	76	78
08:00	4	6	5	85	83
09:00	5	5	80	96	98
10:00	6	81	85	105	104
11:00	83	96	96	122	122
12:00	94	104	108	105	105
13:00	102	120	120	111	112
14:00	120	103	103	108	107
15:00	103	109	109	107	109
16:00	108	103	108	94	96
17:00	102	106	106	100	101

The initial melatonin dosage (i.e. the dosage of day 1) was 20 µg.

Using the formula:

$$\Delta m \geq [\Delta m_{\max} * (\text{ratio} - a)/(1-a)]$$

5

$\Delta m_{\max}$ is set at 40 µg /day

Δm for day 2 was calculated to be 19 µg, Δm for day 3 was calculated to be 13 µg. The overall daily dosage for day 2 was therefore 39 µg, for day 3 it was 52 µg.

10

Fig. 3 shows the drug delivery profiles of the melatonin dosage of

days 1 to 3. As described above, this delivery profile includes an increase of 1-12% (of the total daily melatonin dosage), until about 15% of the daily dose is given in one hour; after that the hourly dose is lowered by 1-12% per hour.

The data of Fig. 3 are given in Table II hereafter.

5

Table II: Melatonin drug delivery profile ($\mu\text{g/h}$)

Clock time	Day 1	Day 2	Day 3
<i>17:00</i>	0	0	1.49
<i>18:00</i>	0.58	1.12	1.5
<i>19:00</i>	0.58	1.13	2.41
<i>20:00</i>	0.93	1.81	3.3
<i>21:00</i>	1.27	2.49	4.1
<i>22:00</i>	1.58	3.09	4.48
<i>23:00</i>	1.73	3.38	5.14
<i>00:00</i>	1.98	3.88	6.82
<i>01:00</i>	2.63	5.14	7.95
<i>02:00</i>	3.07	6	2.94
<i>03:00</i>	1.14	2.22	3.2
<i>04:00</i>	1.23	2.41	2.55
<i>05:00</i>	0.98	1.92	2.02
<i>06:00</i>	0.78	1.52	1.08
<i>07:00</i>	0.42	0.82	0.28
<i>08:00</i>	0.11	0.21	0.86
<i>09:00</i>	0	0.65	0.86
<i>10:00</i>	0	0.65	0.86
<i>11:00</i>	0	0.65	0
<i>12:00</i>	0	0	0
<i>13:00</i>	0	0	0
<i>14:00</i>	0	0	0

- 12 -

15:00	0	0	0
16:00	0	0	0

Please note that the delivery started on Day 3 an hour earlier than in Day 1 and Day 2

Fig. 4 shows a schematic partial cut-out side view of a delivery device 1 according to a first embodiment of the present invention implemented in a watch 10. The upper part of the watch case 10 is shown in front view, whereas the lower part (i.e. those parts referring to the numerals 40-60) is shown in cut-out view.

The device (beside the watch case 10, which also comprises the sensors and computing units for the device) 1 comprises a drug reservoir 40, from which the melatonin may be delivered to the skin 100 of the user and/or the person to be treated by several controllable valves 50. The device 1 is furthermore equipped with an antigliding material 60 located in proximity to the drug reservoir 40 in order to ensure the contact between the drug reservoir 40 and the skin 100.

It should be noted that instead of the valves 50, also further means might be possible to deliver the melatonin. According to one embodiment of the present invention (not shown in the Figs), the device uses electrophoresis to provide active delivery of melatonin.

Fig. 5 shows a top view of the device of Fig. 4 approximately along line II-II in Fig. 4. As can be seen in Fig. 5, the watch case 10 is equipped with several input means 20a, 20b (here in the form of buttons) to set e.g. the desired sleep interval.

Fig. 6 shows a flow chart of an implementation of a method according to a first embodiment of the present invention.

As can be seen from Fig. 6, at first the melatonin is delivered (as expressed by the box "Deliver Melatonin dosed & timed") and the activity is measured ("measure activity"). The measurement of the activity may occur while the melatonin is being delivered as well as after the delivery (as indicated by the "reverse arrow").

- 13 -

Subsequently, the nocturnal and diurnal activity is compared by a comparing means. This comparing means also takes into account possible settings of the desired ratio between the nocturnal and diurnal activity and/or the required sleep interval.

5 In case the melatonin dose does not need to be adjusted (path “no” in the flow chart), the melatonin dosage and timing is continued without a change.

 In case the melatonin dose needs to be adjusted, the change in melatonin dose and/or timing is calculated, taking into account possible settings in the maximum dosage of the melatonin dose as well as the initial melatonin dose.

10 From this change (Δm), the new melatonin dose & timing is calculated.

 The particular combinations of elements and features in the above detailed embodiments are exemplary only; the interchanging and substitution of these teachings with other teachings in this and the patents/applications incorporated
15 by reference are also expressly contemplated. As those skilled in the art will recognize, variations, modifications, and other implementations of what is described herein can occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention as claimed. Accordingly, the foregoing description is by way of example only and is not intended as limiting. The invention's scope is
20 defined in the following claims and the equivalents thereto. Furthermore, reference signs used in the description and claims do not limit the scope of the invention as claimed.

CLAIMS:

5

1. A device for automatic adjustment of the dose of melatonin and/or delivery of melatonin, comprising
 - a) a measuring means, which measures at least one body parameter of a patient for at least ≥ 1 measuring cycle;
 - 10 b) an adapting means, which adapts and/or changes the dose of melatonin according to the measuring data of the measuring means;
 - c) a delivery device for delivering melatonin to a person to be treated and/or a user of the device.
- 15 2. The device according to claim 1, wherein the at least one body parameter includes body temperature, core body temperature, skin surface temperature, activity, melatonin level, cortisol level, heart rate, breathing frequency.
3. The device according to claim 1 or 2, wherein the daily dose of melatonin is set to
20 be
previous dose + Δ melatonin [Δm],
with previous dose being the daily dose of the previous day, whereby Δm is changed and/or set each time period, at least every 14 days, preferably at least every week, but most preferably daily (or for the next time period) in accordance with the data of
25 the measuring means.
4. The device according to any one of the claims 1 to 3, wherein Δm is $\leq 50 \mu\text{g} / \text{day}$, preferably $\leq 40 \mu\text{g} / \text{day}$

30

5. The device according to any one of the claims 1 to 4 wherein Δm is set as

$$\Delta m \geq [\Delta m_{\max} * (\text{ratio} - a)/(1-a)] * 0.8 \text{ and } \leq [\Delta m_{\max_{\text{melatonin}}} * (\text{ratio} - a)/(1-a)] * 1.2$$

with $\Delta m_{\max}$ being the maximum dosage change of melatonin,

- 5 ratio being the actual ratio between nocturnal and diurnal activity, and
a being the desired ratio between nocturnal and diurnal activity.

6. The device according to any one of the claims 1 to 5, whereby the amount of
melatonin delivered is decreased when the ratio and a have differed ≤ 0.1 (i.e.
10 that $|\text{ratio} - a|$ is ≤ 0.1), preferably ≤ 0.05 for at least one measurement cycle,
preferably for at least 5 measurement cycles, the amount of decrease being
preferably $\leq 20\%$ per day and $\geq 5\%$ per day of the dosage of the previous day until m
(melatonin dosage) is $\leq 2.5 \mu\text{g/day}$, preferably $\leq 1.0 \mu\text{g/day}$.

- 15 7. The device according to any one of the claims 1 to 6 wherein the delivery of
melatonin occurs along a drug delivery profile.

8. The device according to any one of the claims 1 to 7 wherein the adapting means is
able to take into account information supplied by the person to be treated and/or a
20 user of the device.

9. A method for the controlled release of drugs, comprising the steps of:
- a) measuring at least one body parameter of the patient for at least ≥ 1 measuring
cycle;
 - 25 b) adapting and/or changing the dose of melatonin according to the measuring data
of the measuring means;
 - c) delivering melatonin to a person to be treated and/or a user of the device.

10. A system incorporating a device according to any one of the claims 1 to 8 and/or the
30 method according to claim 9 and being used in one or more of the following

applications:

- Medical devices for the automatic adjustment of and/or delivery of melatonin;
- Jet-lag treatment devices.

1/5




FIG. 1




FIG. 2

3/5




FIG. 3

4/5




FIG. 4




FIG. 5

5/5




FIG. 6

专利名称(译)	用于自动调节褪黑激素剂量和/或褪黑激素递送的装置		
公开(公告)号	EP2068695A2	公开(公告)日	2009-06-17
申请号	EP2007826250	申请日	2007-09-04
[标]申请(专利权)人(译)	皇家飞利浦电子股份有限公司		
申请(专利权)人(译)	皇家飞利浦电子N.V.		
当前申请(专利权)人(译)	皇家飞利浦电子N.V.		
[标]发明人	KRIJNSEN HENDRIKA C IORDANOV VENTZESLAV P LANGEREIS GEERT VAN BRUGGEN MICHEL P B ACKERMANS PAUL A J		
发明人	KRIJNSEN, HENDRIKA, C. IORDANOV, VENTZESLAV P. LANGEREIS, GEERT VAN BRUGGEN, MICHEL P.B. ACKERMANS, PAUL A.J.		
IPC分类号	A61B5/00 G06F19/00		
CPC分类号	A61B5/1118 A61B5/4806 A61B5/4839 A61M35/00 G06F19/3456 G16H20/10		
优先权	2006120569 2006-09-13 EP		
外部链接	Espacenet		

摘要(译)

本发明涉及一种用于褪黑激素治疗的装置，该装置包括适应装置，该适配装置在测量患者的身体参数或装置的使用者时调整日剂量。